Home/Filings/4/0000899243-21-027015
4//SEC Filing

Stultz Katherine V 4

Accession 0000899243-21-027015

CIK 0001815776other

Filed

Jun 30, 8:00 PM ET

Accepted

Jul 1, 7:01 PM ET

Size

18.5 KB

Accession

0000899243-21-027015

Insider Transaction Report

Form 4
Period: 2021-01-13
Stultz Katherine V
CHIEF OPERATING OFFICER
Transactions
  • Conversion

    Common Stock

    2021-06-29+8,126216,020 total
  • Award

    Series B Preferred Stock

    2021-03-11$5.06/sh+19,763$100,00119,763 total
    Common Stock (8,126 underlying)
  • Award

    Stock Option (right to buy)

    2021-03-17+89,93489,934 total
    Exercise: $6.11Exp: 2031-03-16Common Stock (89,934 underlying)
  • Award

    Stock Option (right to buy)

    2021-01-13+99,75399,753 total
    Exercise: $0.30Exp: 2031-01-12Common Stock (99,753 underlying)
  • Award

    Stock Option (right to buy)

    2021-03-17+209,846209,846 total
    Exercise: $6.11Exp: 2031-03-16Common Stock (209,846 underlying)
  • Conversion

    Series B Preferred Stock

    2021-06-2919,7630 total
    Common Stock (8,126 underlying)
Footnotes (6)
  • [F1]These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.
  • [F2]On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.
  • [F3]This transaction occurred prior to the IPO and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
  • [F4]25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after August 31, 2020, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase.
  • [F5]1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.
  • [F6]The option was granted subject to the achievement by the Company of performance vesting criteria. On June 29, 2021 the performance vesting criteria was met such that the option became reportable. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Issuer

Graphite Bio, Inc.

CIK 0001815776

Entity typeother

Related Parties

1
  • filerCIK 0001864500

Filing Metadata

Form type
4
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 7:01 PM ET
Size
18.5 KB